Independent Conference Highlights of the 2022 ASH Annual Meeting*

Preliminary data through 24 weeks suggest encouraging efficacy with selinexor plus ruxolitinib based on improvements in spleen volume, total symptom score, and hemoglobin stabilization.

Adding the PI3K inhibitor parsaclisib to ruxolitinib reduced spleen volume and improved symptom burden in patients with myelofibrosis and an inadequate response to ruxolitinib.

Navitoclax plus ruxolitinib achieved improved SVR₃₅, including in risk groups associated with poor prognosis, along with reductions in bone marrow fibrosis and variant allele frequency of driver gene mutations.

Emerging data with ruxolitinib show clinically meaningful activity and reductions in splenomegaly and disease-related symptoms in patients with CMML.

Low-dose lenalidomide prolonged time to transfusion dependency compared with placebo in patients with low-risk MDS and del(5q).

LFS and OS analysis using 2022 WHO and ICC MDS classification systems applied to a large, single-institution patient database suggests potential improvements.

Updated data from the phase III MOMENTUM trial show that momelotinib maintained symptom responses, transfusion independence, and spleen responses originally achieved by Week 24 through Week 48.

Ropeginterferon alfa-2b treatment of patients with low/intermediate-1–risk, prefibrotic primary myelofibrosis shows early evidence of promising efficacy and a safety profile warranting further study.

In patients with PV and ET treated with long-term ruxolitinib, JAK2 V617F complete molecular response or deep molecular response occurred in 18% of patients and was associated with lower risk of progression to secondary MF

Sabatolimab plus a hypomethylating agent (azacitidine or decitabine) did not yield statistically significant improvement in CR and PFS in patients with higher-risk MDS.